micro-community-banner
 
Profile Image
  • Add Media
  • Saved

1yr
infographic
Profile Image
  • Saved

1yr
infographic
Profile Image
  • Saved

1yr
infographic
Profile Image
  • Saved

1yr
Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial - PubMed

Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38678642/

Absolute mass changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B can explain results of the PROMINENT trial. The 3 mg/dL (0.08 mmol/L) higher total atherogenic cholesterol together with 5...

The study suggests that absolute changes in remnant cholesterol, LDL cholesterol, and apolipoprotein B explain the neutral results of the PROMINENT trial, with higher atherogenic cholesterol and apolipoprotein B linked to more ASCVD.

Profile Image
  • Saved

1yr
Higher Cholesterol Absorption Marker at Baseline Predicts Fewer Cardiovascular Events in Elderly Patients Receiving Hypercholesterolemia Treatment: The KEEP Study - PubMed

Higher Cholesterol Absorption Marker at Baseline Predicts Fewer Cardiovascular Events in Elderly Patients Receiving Hypercholesterolemia Treatment: The KEEP Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38240241/

URL: https://www.umin.ac.jp; unique identifier: UMIN000017769.

The KEEP study found that higher baseline campesterol levels in older individuals with hypercholesterolemia were associated with a lower risk of cardiovascular events, regardless of ezetimibe treatment.

Profile Image